Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The RECOVERY trial tests a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Patients were randomised to receive dexamethasone 6 mg once per day for ten days and were compared with patients receiving usual care alone. Dexamethasone reduced deaths by one-third in ventilated patients and by one-fifth in other patients receiving oxygen only; there was no benefit among those patients who did not require respiratory support. Based on these results, 1 death would be prevented by treatment of around 8 ventilated patients or around 25 patients requiring oxygen alone.